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Bridging the Gap Between Doctor and Patient Utilization and Understanding of BRCA1/2 
Mutation Testing 
 
I. Introduction 
 
With the early detection of deadly diseases in mind, genetic testing is growing more and 
more important in the practice of medicine. Genetic testing has evolved greatly since its rise in 
utility over the past two decades. As in all forms of medical screening, however, doctors must 
carefully weigh the benefits and risks in referring patients for genetic testing. In 2005, the US 
Preventive Services Task Force (USPSTF) issued a recommendation against routine BRCA 
genetic testing for breast and ovarian cancer on the basis that only a small population of women 
are actually genetically predisposed to the harmful genetic mutations associated with these types 
of cancer.
1
 According to the USPSTF, risks such as false-positive and false-negative results and 
other psychological and behavioral outcomes greatly outweigh any potential benefit to routine 
screening for women without specific family history patterns.
2
 Despite the USPSTF 
recommendation, 89% of primary care physicians have indicated needs for more clinical 
guidelines for genetic testing for cancer susceptibility.
3
 One problem seems to be that, although 
doctors recognize the growing importance of genetics regardless of their field of medicine, many 
feel they have inadequate resources to meet the demands of their practice. Another problem is 
that patients may be exacerbating the issue by overestimating their risks for BRCA mutations and 
needlessly requesting testing themselves. 
This paper will explore the issues related to doctor and patient utilization and 
understanding of clinical guidelines to genetic predisposition testing using the case study of the 
                                                 
1 U.S. Preventive Servs. Task Force, Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian 
Cancer Susceptibility: Recommendation Statement, 143 ANNALS INTERNAL MED. 355 (2005), http://www.uspreven 
tiveservicestaskforce.org/uspstf05/brcagen/brcagenrs.pdf [hereinafter USPSTF]. 
2 Id. 
3 See Robert Klitzman, Attitudes and Practices Among Internists Concerning Genetic Testing, 22 J. GENETIC 
COUNSELING 90, 91 (2013). 
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USPSTF recommendations for BRCA mutation testing. Part II will discuss the BRCA1/2 genes 
and mutations, the various risk assessment tools and methods that are used as screening devices, 
and the DNA sequencing test. Part III will discuss the report used by the USPSTF in making its 
recommendation. Part IV will discuss the issues related to physician and patient use and 
understanding of genetic screening for cancer susceptibility. Finally, Part V will contain my 
recommendations for how to address the issues raised in Part IV.   
II. The BRCA 1/2 Genes, Mutations, and Tests 
  
A. The BRCA1/2 Genes and Mutations 
 
Doctors and geneticists have identified two genes related to breast and ovarian cancer in 
women: BRCA1 and BRCA2. The names BRCA1 and BRCA2, respectively, stand for breast 
cancer susceptibility gene 1 and breast cancer susceptibility gene 2.
4
 Although the functions of 
BRCA1 and BRCA2 are interrelated, their structures are quite different. 
BRCA1 is a tumor-suppressor gene that is important in regulating the growth of breast 
epithelial cells.
5
 As a tumor-suppressor gene, the BRCA1 gene produces a protein that helps 
prevent cells from growing and dividing too rapidly or in an uncontrolled way.
6
 The human 
BRCA1 gene is located on the long (q) arm of chromosome 17 at region 2 band 1, from base pair 
41,196,312 to base pair 41,277,500.
7
 The BRCA1 gene was first identified by the King 
Laboratory at UC Berkeley in 1990.
8
 Later, scientists at the University of Utah, National Institute 
of Environmental Health Sciences (NIEHS), and Myriad Genetics cloned the gene for the first 
                                                 
4 See Nat’l Cancer Inst., BRCA1 & BRCA2: Cancer Risk and Genetic Testing, 
http://www.cancer.gov/cancertopics/factsheet/Risk/BRCA (reviewed May 29, 2009). 
5 See J. Fergus Couch ET AL., BRCA1 Mutations in Women Attending Clinics That Evaluate the Risk of Breast 
Cancer, 336 NEW ENG. J. MED. 1409, 1409 (1997).  
6
 See Genetics Home Reference, BRCA1, http://ghr.nlm.nih.gov/gene/BRCA1 (reviewed Aug. 2007) [hereinafter 
Genetics Home Reference, BRCA1]. 
7 See J.A. Duncan ET AL., BRCA1 & BRCA2 Proteins: Roles in Health and Disease. UNIV. DEP’T SURGERY, 
GLASGOW ROYAL INFIRMARY (1998). 
8 See JM Hall ET AL., Linkage of Early-Onset Familial Breast Cancer to Chromosome 17q21, 250 SCIENCE (1990). 
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time in 1994.
9
 It is critical for the repair of double-strand DNA breaks (DSBs) and interstrand 
crosslinks (ICLs) by homologous recombination (HR).
10
 These breaks can be caused by natural 
and medical radiation or other environmental exposures, and also occur when chromosome 
exchange genetic material in preparation for cell division.
11
 Researchers believe that the BRCA1 
protein also regulates the activity of other genes and plays a critical role in embryonic 
development.
12
  
There are more than 1,000 mutations in the BRCA1 gene.
13
 The majority of these 
mutations lead to the production of an abnormally short version of the BRCA1 protein, or prevent 
any protein from being made from one copy of the gene.
14
 The most common mutations are a 
deletion of adenine and guanine (185delAG) and an insertion of cytosine (5382insC).
15
 A 
defective or missing BRCA1 protein is unable to help repair damaged DNA or fix mutations that 
occur in other genes. When these defects accumulate, the uncontrolled growth and division of 
cells can form a tumor.
16
 BRCA1 mutations account for 45 percent of hereditary cases of breast 
cancer and 80 to 90 percent of hereditary cases of combined breast and ovarian cancer.
17
 
Harmful BRCA1 mutations may also increase a woman’s risk of cervical, uterine, pancreatic, and 
colon cancer.
18
  
                                                 
9 See Hall, supra note 8. 
10 See Shane R. Stecklein ET AL., BRCA1 and HSP90 Cooperate in Homologous and Non-Homologous DNA 
Double-Strand-Break Repair and G2/M Checkpoint Activation, 109 PROC. NAT’L ACAD. SCI. 13650, 13651 (2012). 
11 See Genetics Home Reference, BRCA1, supra note 6. 
12 Id. 
13 Id. 
14 Id. 
15 See Couch, supra note 5 at 1409. 
16 See Genetics Home Reference, BRCA1, supra note 6. 
17 See Couch, supra note 5 at 1409. 
18 See Nat’l Cancer Inst., supra note 4. 
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The BRCA2 gene also belongs to the tumor-suppressor gene family.
19
 Like the BRCA1, it 
is similarly important for the regulation of cell growth and division.
20
 It is located on the long (q) 
arm of chromosome 13 at position region 12 band 3 from base pair 32,889,616 to 32,973,808.
21
 
The BRCA2 gene was first cloned by scientists at Myriad Genetics, Endo Recherche, Inc., HSC 
Research and Development Limited Partnership, and University of Pennsylvania.
22
 Research 
shows that the BRCA2 protein may also help regulate cytokinesis, which is the step in cell 
division when the cytoplasm divides to form two separate cells.
23
 There are approximately 800 
different mutations associated with the BRCA2 gene.
24
 Many of the mutations disrupt protein 
production from one copy of the gene in each cell, resulting in an abnormally small, 
nonfunctional version of the BRCA2 protein.
25
 Harmful BRCA2 mutations may additionally 
increase the risk of pancreatic cancer, stomach cancer, gallbladder and bile duct cancer, and 
melanoma.
26
  
The next two sections will explain how patients are tested for BRCA1/2 mutation 
susceptibility. There are two methods: risk assessment testing and DNA sequencing. Risk 
assessment testing is typically completed first to determine whether DNA sequencing is 
warranted. 
B.  Risk Assessment Testing for BRCA1/2 Mutation Among Women 
 There are two important types of testing related to breast and ovarian cancer 
susceptibility: risk assessment testing and DNA sequencing. Risk assessment is important 
                                                 
19
 See Genetics Home Reference, BRCA2, http://ghr.nlm.nih.gov/gene/BRCA2 (reviewed Aug. 2007) [hereinafter 
Genetics Home Reference, BRCA2]. 
20 Id. 
21 See Duncan, supra note 7. 
22 Id. 
23 See Nat’l Cancer Inst., supra note 4. 
24 Id. 
25 Id. 
26 Id. 
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because guidelines recommend testing for mutations only when an individual has personal or 
family history features suggestive of inherited cancer susceptibility.
27
 Although the BRCA1/2 
mutations can occur in anyone, certain specific family history patterns are associated with an 
increased risk for mutation. For example, specific BRCA mutations are clustered among certain 
ethnic groups, such as Ashkenazi Jews, and among families in the Netherlands, Iceland and 
Sweden.
28
 For non-Ashkenazi Jewish women, patterns associated with an increased risk for 
BRCA1/2 mutation include two first-degree relatives with breast cancer, one of whom received 
the diagnosis at age 50 years or younger; a combination of three or more first- or second-degree 
relatives with breast cancer regardless of age at diagnosis; a combination of both breast and 
ovarian cancer among first- and second-degree relatives; a first-degree relative with bilateral 
breast cancer; a combination of two or more first- or second-degree relatives with ovarian cancer 
regardless of age at diagnosis; a first- or second-degree relative with both breast and ovarian 
cancer at any age; and a history of breast cancer in a male relative.
29
 About two percent of adult 
women in the general population have an increased-risk family history as defined above.
30
 Those 
women that do not fall into any of the increased family history patterns have a low probability of 
having a deleterious mutation in BRCA1 or BRCA2 genes.
31
 It is important to remember that 
developing breast or ovarian cancer does not necessarily automatically follow from a BRCA 
mutation. The probability of developing breast or ovarian cancer by age 70 years in a woman 
                                                 
27 See HD Nelson ET AL., Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer 
Susceptibility: Systematic Evidence Review for the U.S. Preventive Services Task Force, ANNALS INTERNAL MED. 
(2005), http://www.ncbi.nlm.nih.gov/books/NBK43308. 
28 See USPSTF, supra note 1. 
29 Id. 
30 Id. 
31 Id. 
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who has a clinically important BRCA mutation, is estimated to be 35 percent to 84 percent for 
breast cancer and 10 to 50 percent for ovarian cancer.
32
 
There are several different risk tools for predicting risk for deleterious BRCA1/2 
mutations. The four most widely used risk tools include the Myriad Genetic Laboratories model, 
the Couch model, BRCAPRO, and the Tyrer model.
33
 Unfortunately, no studies of their 
effectiveness in a primary care screening population are available, as much of the data from these 
models are from women with existing cancer, and their applicability to asymptomatic, cancer-
free women in the general population is unknown.
34
 
There are two Myriad Genetic Laboratories models. The first model is used exclusively 
to predict risk for BRCA1 mutation and is based on a population of women with either early-
onset breast cancer or ovarian cancer, or with a family history of breast or ovarian cancer.
35
 This 
logistic regression model also takes into account bilateral breast cancer, age of diagnosis, and 
Ashkenazi Jewish ancestry, and is not dependent on affected relatives.
36
 The second model 
predicts risk for both BRCA1 and BRCA2 mutations and is based on a population of women with 
breast cancer under age 50 or ovarian cancer who have at least one first- or second-degree 
relative with early breast and ovarian cancer.
37
 This model considers bilateral breast cancer, 
concurrent breast and ovarian cancer, and breast cancer under age 40.
38
 
The second risk assessment tool is the Couch Model. This model is based on logistic 
regression of data from a population of women with breast cancer and a family history of breast 
                                                 
32 See USPSTF, supra note 1. 
33 See Nelson, supra note 27. 
34 See USPSTF, supra note 1. 
35 See D Shattuck-Eidens ET AL., BRCA1 Sequence Analysis in Women at High Risk for Susceptibility Mutations. 
Risk Factor Analysis and Implications for Genetic Testing, 278 J. AM. MED. ASS’N 1242, 1245 (1997). 
36 Id. 
37 Id. 
38 Id. 
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and/or ovarian cancer, and predicts risk for BRCA1 mutation.
39
 The original model determined 
mutations by conformation sensitive gel electrophoresis (CSGE) rather than DNA full 
sequencing, which potentially underestimated mutation prevalence.
40
 The refined model includes 
both BRCA1 and BRCA2 mutations using DNA full sequencing.
41
 This model does not require 
the individual to have breast or ovarian cancer, however the family must have more than two 
cases of breast cancer.
42
 Some of the predictors used in the Couch model include the number of 
women diagnosed with breast cancer under age 50, concurrent breast and ovarian cancer, ovarian 
cancer, male breast cancer, and Ashkenazi Jewish ancestry.
43
 
The third risk assessment tool is the BRCAPRO model. The BRCAPRO model is a 
Bayesian model that provides estimates of risk for BRCA1 and BRCA2 mutations.
44
 It has been 
validated in populations of women with increased prevalence of specific mutations.
45
 In 
BRCAPRO, the individual may or may not have breast or ovarian cancer.
46
 It considers factors 
such as current age, age at diagnosis, bilateral breast cancer, concurrent breast and ovarian 
cancer, all first- and second-degree relatives with and without cancer, males with breast cancer, 
and Ashkenazi Jewish ancestry.
47
 It includes information on both affected and unaffected 
relatives.
48
 
                                                 
39 See Couch, supra note 5 at 1411. 
40 See Nelson, supra note 27. 
41
 See MA Blackwood ET AL., Predicted Probability of Breast Cancer Susceptibility Gene Mutations. 69 BREAST 
CANCER RESEARCH AND TREATMENT (2001). 
42 See Nelson, supra note 27.  
43 Id. 
44
 See DA Berry ET AL., Probability of Carrying a Mutation of Breast-Ovarian Cancer Gene BRCA1 Based on 
Family History, 89 J. NAT’L CANCER INST. 227, 229 (1997) [hereinafter Berry, Probability]. 
45 See DA Berry DA ET AL., BRCAPRO Validation, Sensitivity of Genetic Testing of BRCA1/BRCA2, and 
Prevalence of Other Breast Cancer Susceptibility Genes, 20 J. CLINICAL ONCOLOGY 2701, 2702 (2002) [hereinafter 
Berry, BRCAPRO]. 
46 See Nelson, supra note 27. 
47 Id. 
48 Id. 
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The fourth model is the Tyrer model. This model provides a comprehensive risk estimate 
using personal risk factors in combination with a genetic analysis.
49
 Similar to the Couch model 
and BRCAPRO, the individual is not required to have breast or ovarian cancer.
50
 The model 
includes personal risk factors such as current age, age at menarche, parity, age at first childbirth, 
age at menopause, atypical hyperplasia, lobular carcinoma in situ, height, and body mass index 
(BMI).
51
 As part of the genetic analysis, the model incorporates the high-risk, high-penetrance 
BRCA1 and BRCA2 germline mutations with the addition of a low-penetrance gene.
52
 The low-
penetrance gene is included as a stand-in to account for the effect of all other unidentified 
genes.
53
 The Tyrer Model is run through a computer program that is still not yet widely 
distributed.
54
 The program uses segregation analysis techniques based on Bayes’ theorem to 
determine the risk of BRCA1/2 mutations.
55
 
As mentioned supra, the effectiveness of risk assessment tools such as the Myriad 
Genetic Laboratories model, Couch model, BRCAPRO, and Tyrer model is unknown in a 
primary care setting. Primary care physicians do, however, have access to three other risk 
assessment tools for potential BRCA1/2 mutations. These tools are the Family History Risk 
Assessment Tool (FHAT), the Manchester scoring system, and the Risk Assessment in Genetics 
(RAGs) tool.
56
 Using these risk tools, primary care physicians can manage recommendations of 
                                                 
49 See J Tyrer ET AL., A Breast Cancer Prediction Model Incorporating Familial and Personal Risk Factors, 
23 STATISTICS IN MEDICINE 1111, 1112 (2004). 
50 See Nelson, supra note 27. 
51 Id. 
52 Id. 
53 Id. 
54 Id. 
55 Id. 
56 See CA Gilpin ET AL., A Preliminary Validation of a Family History Assessment Form to Select Women at Risk 
for Breast or Ovarian Cancer for Referral to a Genetics Center, 58 CLINICAL GENETICS 2999, 3002 (2000). 
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reassurance, referral to a breast clinic, or referral to a geneticist on the basis of the patient’s 
respective risk categories.
57
  
The FHAT helps clinicians select patients for referral to genetic counseling.
58
 This tool 
uses a point system based on the number of relatives, third-degree or closer, diagnosed with 
breast, ovarian, colon, or prostate cancer, and the relationship to the individual being evaluated, 
age at diagnosis, and type and number of primary cancers.
59
 If a patient receives a score of 10 
points or higher, then the doctor should refer her for genetic counseling.
60
 The sensitivity and 
specificity of FHAT for a clinically significant BRCA1 or BRCA2 mutation were 94% and 51%, 
respectively.
61
 
The Manchester scoring system is a risk assessment tool developed in the U.K. to predict 
deleterious BRCA1/2 mutations at the 10% likelihood level.
62
 Similar to the FHAT, the 
Manchester scoring system assigns points depending on the type of cancer (breast, ovarian, 
pancreatic, or prostate) affected family members, and age at diagnosis and provide scores for 
BRCA1 and BRCA2 mutations separately.
63
 The Manchester model had 87% sensitivity and 66% 
specificity for combined BRCA1 and BRCA2 mutations, which compared well with other models 
tested.
64
 
The Risk Assessment in Genetics (RAGs) tool is a computer program used to assess and 
manage family breast and ovarian cancer in primary care settings.
65
 Using information about the 
patient and relatives, including family history and the age of the presenting patient, RAGs 
                                                 
57 See USPSTF, supra note 1. 
58 See Gilpin, supra note 56. 
59 See Nelson, supra note 27. 
60 Id. 
61 Id. 
62 See DG Evans ET AL., A New Scoring System for the Chances of Identifying a BRCA 1/2 Mutation Outperforms 
Existing Models Including BRCAPRO, 41 J. MED. GENETICS 474 (2004). 
63 See Nelson, supra note 27. 
64 Id. 
65 Id. 
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generates categories of risk for breast and ovarian cancer, referral guidelines, and suggests 
appropriate management. This tool assigns one of three risk levels: low (<10% risk of having a 
clinically significant BRCA1/2 mutation), in which the patient is reassured and managed in 
primary care; moderate (10-25% risk), in which the patient is referred to a breast clinic; and high 
(>25% risk, in which the patient is referred to a clinical geneticist.
66
 Tested against other primary 
care risk assessment tools, RAGs resulted in significantly more appropriate management 
decisions and more accurate pedigrees, and was the preferred approach.
67
 Moreover, RAGs took 
on average 178 seconds to administer.
68
 
In sum, primary care physicians have numerous risk assessment tools at their disposal in 
order to determine a patient’s risk for a genetic predisposition to a BRCA1/2 mutation. Using 
these tools, a physician will classify women according to the risk group that they fall in. In the 
case of a patient falling into a low or moderate-risk group, a doctor will recommend against 
further testing. Alternatively, if the patient falls into a high-risk category, further testing should 
be recommended. Women who are classified as being at high-risk for a BRCA1/2 mutation go on 
to DNA sequencing testing, which is described in the next section. 
C. DNA Sequencing Tests for the BRCA1/2 Mutations 
 The second type of testing for susceptibility to breast and ovarian cancer is DNA 
sequencing for clinically significant BRCA1/2 mutations. Guidelines for testing recommend 
DNA sequencing only for women in the high-risk category as defined above.
69
 Nevertheless, any 
woman could request testing on her own regardless of her personal risk factor. Several clinical 
laboratories in the United States test for specific mutations or sequence-specific exons. 
                                                 
66
 See Nelson, supra note 27. 
67 Id. 
68 Id. 
69 Id. 
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Individuals without linkages to others with known mutations undergo direct DNA sequencing. In 
these cases, guidelines recommend that testing begin with a relative who has known breast or 
ovarian cancer to determine whether a clinically significant mutation is segregating in the 
family.
70
 Myriad Genetic Laboratories provides direct DNA sequencing in the United States and 
reports analytic sensitivity and specificity exceeding 99 percent.
71
 
72
 Test results include not only 
positive (denoting a deleterious mutation) and negative (no mutation found) interpretations, but 
also variants of uncertain clinical significance.
73
 Approximately 13 percent of all those tested 
will have results with uncertain clinical significance.
74
 For testing, a small sample of blood must 
be drawn or an oral rinse sample taken.
75
 DNA sequencing can take up to two weeks for 
results.
76
 DNA sequencing tests can cost several hundred dollars, although some insurance 
companies will cover the cost.
77
 
 This section discussed the BRCA1/2 genes and mutations and also the two methods for 
screening for the mutations. Now, it is time to turn to the USPSTF recommendations and the 
study that provided the foundation for those recommendations. The study relied on the answers 
to five key questions to issue its conclusions for the USPSTF to review. Those key questions are 
answers are discussed in the next section. 
III. Analysis of the Nelson Study, 2005 US Preventive Services Task Force 
Recommendation, and Recommendations of Other Professional Medical Groups 
                                                 
70 See Nelson, supra note 27. 
71 Id.  
72 Analytic sensitivity refers to the proportion of actual positives results that are correctly identified. This is 
sometimes called the true positive value. For example, sensitivity refers to the percentage of sick people who are 
correctly identified as having the condition. Specificity, however, measures the proportion of negative that are 
correctly identified. For example, the specificity of a study would show the percentage of healthy people who are 
correctly identified as not having the condition. This is sometimes called the true negative value. 
73 See Nelson, supra note 27. 
74 Id. 
75 See Myriad Genetics, Genetic Testing Process, http://www.myriad.com/physicians/genetic-testing/genetic-testing-
process-2/ (last visited May 5, 2103). 
76 Id. 
77 See Nelson, supra note 27. 
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A. Discussion of the Nelson Study, Five Key Questions, and USPSTF Recommendations 
Concerned with the growing public interest in BRCA testing, despite the rarity of 
mutations in the general population, the USPSTF commissioned a research group to determine 
the benefits and harms of screening for inherited breast and ovarian cancer susceptibility in the 
general population of women without cancer presenting for primary health care in the United 
States.
78
 The study was published in 2005 in the ANNALS OF INTERNAL MEDICINE. The research 
was funded by the Centers for Disease Control and Prevention under a contract with the Agency 
for Healthcare Research and Quality.
79
 The ultimate recommendations issued by the USPSTF 
were based on the responses to five key questions investigated in the Nelson study.  
The first key question is whether risk assessment and BRCA mutation testing leads to a 
reduction in the in the incidence of breast and ovarian cancer and cause-specific or all-cause 
mortality. The research group found that no studies demonstrate that a screening approach 
consisting of risk assessment in a primary care setting followed by BRCA mutation testing and 
preventive interventions for appropriate candidates ultimately reduces the incidence of breast and 
ovarian cancer and cause-specific or all-cause mortality.
80
 
The second key question investigates how well clinicians in a primary care setting select 
candidates BRCA mutation testing using risk assessment. The Nelson study began by identifying 
three methods used by primary care physicians to complete risk assessment for cancer 
susceptibility. The most important method is a determination of family history. Decisions about 
referral, testing, and prevention interventions are often based on self-reports of family histories 
that include types of cancers, relationships within the family, and ages of onset. Appropriate 
                                                 
78 See Nelson, supra note 27. The research was conducted by Heidi D. Nelson, MD, MPH; Laurie Hoyt Huffman, 
MS; Rongwei Fu, PhD; and Emily L. Harris, PhD, MPH. The report published by Nelson, Huffman, Fu, and Harris 
will hereinafter be referred to as the Nelson study. 
79 See Nelson, supra note 27. 
80 Id. 
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decisions rely on family histories that are accurately reported by women and correctly obtained 
by clinicians.
81
 One study determined the sensitivity and specificity of a family history of breast 
or ovarian cancer in first-degree relatives reported by individuals without cancer to be more 
reliable with respect to breast cancer than ovarian cancer. Specifically, the study found a 
sensitivity of 82 percent and specificity of 91 percent with respect to breast cancer, but 50 
percent and 99 percent, respectively, for ovarian cancer.
82
 
Risk assessment tools are the second method utilized to determine how well primary care 
physicians select candidates for BRCA mutation testing. As discussed above, there are several 
different tools and methods available to primary care physicians such as the Myriad Genetics 
model, the Couch model, BRCAPRO, the Tyrer model, and others. Their effectiveness in 
screening the general population is unknown.  
Finally, the third method is referral guidelines. In order to help primary care physicians 
identify women at potentially increased risk for BRCA mutations, health maintenance 
organizations, professional organizations, cancer programs, state and national health programs, 
and investigators develop referral guidelines. Most include questions about personal and family 
history of BRCA mutations, breast and ovarian cancer, age of diagnosis, bilateral breast cancer, 
and Ashkenazi Jewish heritage.
83
 Moreover, most guidelines are not intended to lead directly to 
testing, but instead lead to a referral for more extensive genetic evaluation and counseling.
84
 The 
effectiveness of referral guidelines is still unknown as no studies have been conducted to 
measure the efficacy of the guidelines.
85
 
                                                 
81 See Nelson, supra note 27. 
82 RA Kerber & ML Slattery, Comparison of Self-Reported and Database-Linked Family History of Cancer Data in 
a Case-Control Study, 146 AM. J. EPIDEMIOLOGY 244, 245 (1997). 
83See Nelson, supra note 27. 
84 Id. 
85 Id. 
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Thus, the Nelson study determined that primary care physicians use three different 
methods in selecting candidates for BRCA mutation testing: family history, risk assessment tools, 
and referral guidelines. Despite the fact that primary care physicians have a multitude of 
different resources at their fingertips, it is generally unknown how effective these methods are in 
the general population among asymptomatic women. Moreover, the use of these methods will 
increase the amount of time doctors will have to spend with each patient, something doctors may 
be unwilling to do if they must see a high volume of patients each day. Still, risk assessment, 
particularly through a collection of family history information, may be a cheap and effective way 
to conduct risk assessment because many primary care physicians collect family history 
information as part of their routine exam. Overall, more research needs to be done on the 
effectiveness of these three methods in the general population among asymptomatic women. 
 The third key question explores the benefits of genetic counseling before testing. On the 
one hand, there are no studies that determine the physical benefits of genetic counseling before 
testing. That is to say that no studies describe cancer or mortality outcomes related to genetic 
counseling.
86
 On the other hand, there are ten studies that measure the psychological and 
behavioral outcomes associated with genetic counseling before testing.
87
 These studies 
specifically looked to measure the impact of genetic counseling on breast cancer worry, anxiety, 
                                                 
86 See Nelson, supra note 27. 
87 See DJ Bowen, Breast Cancer Risk Counseling Improves Women’s Functioning, 53 PATIENT EDUC. COUNSELING 
79, 81 (2004); DJ Bowen, Effects of Risk Counseling on Interest in Breast Cancer Genetic Testing for Lower Risk 
Women, 4 GENETICS MED. 359, 362 (2002); W Burke, Genetic Counseling for Women with an Intermediate Family 
History of Breast Cancer, 90 AM. J. MED. GENETICS 361, 363 (2000); A Cull, The Use of Videotaped Information in 
Cancer Genetic Counseling, 77 BRIT. J. CANCER 830, 831 (2000); C Lerman, Racial Differences in Testing 
Motivation and Psychological Distress Following Pretest Education for BRCA1 Gene Testing, 8 CANCER 
EPIDEMIOLOGY BIOMARKERS PREV. 361, 362 (1999); C Lerman, A Randomized Trial of Breast Cancer Risk 
Counseling, 15 HEALTH PSYCHOL. 75, 75 (1996); C Lerman, Effects of Individualized Breast Cancer Risk 
Counseling, 87 J. NAT’L CANCER INST. 286, 288 (1995); E Lobb, The Use of Audiotapes in Consultations with 
Women from High Risk Breast Cancer Families. 39 J. MED. GENETICS 697, 698 (2002); M Watson, Family History 
of Breast Cancer. 35 J. MED. GENETICS 731, 732 (1998); MJ Green, Effect of a Computer-Based Decision Aid on 
Knowledge, Perceptions, and Intentions About Genetic Testing for Breast Cancer Susceptibility, 292 J. AM. MED. 
ASS’N 442, 444 (2004). 
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depression, perception of cancer risk, and intent to participate in genetic testing. Nine of the ten 
studies reported a decrease in psychological distress or no effect after counseling.
88
 Five trials 
showed increased accuracy of perception of cancer risk among women who received genetic 
counseling.
89
 One study showed less accurate risk perception after genetic counseling and one 
had mixed results.
90
 In conclusion, there is no data that suggests genetic counseling before 
testing has any physical benefit; however, a majority of studies report either a positive 
psychological impact or no impact at all. 
The fourth key questions measures how well BRCA mutation testing predicts risk for 
breast or ovarian cancer among women with family histories predicting an average, moderate, or 
high risk for a deleterious mutation. This key question incorporates two issues. First, it is 
important to define which women qualify as either possessing an average, moderate or high risk 
for a deleterious mutation. A woman with an average risk has no first-degree relatives and no 
more than one second-degree relative on each side of the family with breast or ovarian cancer.
91
 
A woman has a moderate risk if she has one first-degree relative or two second-degree relatives 
on the same side of the family with breast or ovarian cancer.
92
 Lastly, a woman has a high risk if 
she has at least two first-degree relatives with breast or ovarian cancer.
93
 
 The second issue is addressing how to measure the efficacy of BRCA mutation testing in 
identifying risk for breast and ovarian cancer. One method is to look at the prevalence of BRCA1/2 
mutations in women. Nelson’s study estimated the prevalence of BRCA1 and BRCA2 mutations in 
women at average risk could be as high as .24%, moderate risk to be .24% to 3.4%, and high risk to 
                                                 
88 See Nelson, supra note 27. 
89 Id. 
90 Id. 
91 Id. 
92 Id. 
93 Id. 
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be 8.7% and above.
94
 Other models estimate the prevalence of deleterious mutation in the non-
Jewish US population to be about 1 in 300 to 500 persons.
95
 Still another model estimates the 
prevalence among women with a strong family history of cancer to be 8.7%.
96
 These numbers are 
remarkable in that they show just how rarely BRCA1/2 mutations occur in average or moderate risk 
groups.  
 The second method for determining how well BRCA mutation testing predicts risk for 
breast and ovarian cancer is to look at the penetrance. Penetrance is the probability of developing 
breast or ovarian cancer among women who have a clinically significant BRCA1 or BRCA2 
mutation.
97
 For breast cancer, Nelson’s study estimates BRCA1 penetrance to age 75 years are 
68.8% in average-risk groups; 49.9% in moderate-risk groups, and 60.5% in high-risk groups.
98
 
BRCA2 penetrance estimates are only available for the high-risk group: 53.0%.
99
 For ovarian 
cancer, BRCA1 penetrance estimates to age 75 years are 29.2% in average-risk groups, 55.1% in 
moderate-risk groups, and 26.1% in high-risk groups. BRCA2 penetrance estimates for ovarian 
cancer are 34.2%, 27.0%, and 6.4%.
100
 These numbers show that a woman with a deleterious 
mutation does not automatically develop breast or ovarian cancer. In addition, there does not 
seem to be an obvious correlation between either a BRCA1 or BRCA2 mutation and breast or 
ovarian cancer across women in different risk groups.  
 The fifth key question explores the adverse effects of risk assessment, genetic counseling, 
and testing. This is an important step in order to way both the benefits and Two important 
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adverse effects of risk assessment, genetic counseling, and testing are false-positive and false-
negative results that could occur at each step of screening for a BRCA1/2 mutation. False-
positive and false-negative results are especially troublesome because that can lead to 
inappropriate reassurance or intervention.
101
 An obvious example would be a woman that 
unnecessarily undergoes chemoprevention as a result of a false-positive result of the DNA 
sequencing screening. False-positive and false-negative results are not exclusive to BRCA1/2 
mutation screening. But, considering the serious and often drastic preventive measures that may 
follow from a false-positive result, the harm in subjecting oneself to a questionably beneficial 
test seems to substantially any benefit. Unfortunately, no studies directly address these issues.
102
 
 Another potential adverse effect is emotional distress. Nelson’s study focused on nine 
studies that assessed breast cancer risk assessment, genetic testing, and genetic counseling their 
subsequent impact on distress measured as breast cancer worry, anxiety, or depression.
103
 
According to Nelson, more studies showed decreased cancer worry or anxiety after risk assessment 
and testing.
104
 There were mixed results as to depression.
105
 Distress varied according to whether 
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studies evaluated risk assessment, genetic testing, or both.
106
 In four studies that evaluated risk 
assessment, most measures of breast cancer worry, anxiety, and depression decreased, and only 1 
measure of breast cancer worry increased.
107
 When genetic testing was evaluated, breast cancer 
worry and anxiety increased, and results for depression were mixed. 
108
  
 Lastly, there are several adverse effects associated with interventions for women 
identified as high risk by history, positive genetic test results, or both.
109
 Women with known 
mutations typically undergo one to three annual breast cancer screen examinations. The four 
most popular, intensive cancer screening methods are magnetic resonance imaging (MRI), 
mammography, ultrasonography, and clinical breast examinations. Use of MRI, ultrasonography, 
and mammography together had a sensitivity of 95%.
110
 Nelson did not identify any studies 
describing the adverse effects of intensive cancer screening for breast or ovarian cancer. 
However, her study did mention potential adverse effects such as inconvenience of frequent 
examinations and procedures, exposure to ionizing radiation that could increase risk for breast 
cancer, cost, harms resulting from false-positive finding and subsequent testing and biopsies, and 
false reassurance for women who may have increased risks for developing cancer between 
periodic cancer screening tests.
111
 Other serious adverse effects are associated with 
chemoprevention and prophylactic surgery (mastectomy and oophorectomy), both of which may 
follow as interventions for women identified as high risk by history, positive genetic test results, 
or both.
112
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 In conclusion, Nelson’s study uncovered two important points. First, Nelson explained 
that more information is needed about the impact of screening in the general population in order 
to determine the appropriateness of risk assessment and testing for BRCA mutations in primary 
care.
113
 While primary care physicians have a number of risk assessment tools at their disposal, 
their effectiveness is not known among asymptomatic women in the general population. 
Secondly, Nelson concluded that there are significant potential harms related to BRCA mutation 
testing among women in the general population. Using these conclusions, the USPSTF issued its 
recommendation, which are discussed below. 
In its recommendation statement, the USPSTF made two significant recommendations. 
First, the USPSTF recommended against routine referral for genetic counseling or routine BRCA 
testing for women whose family history is not associated with an increased risk for deleterious 
BRCA1/2 mutations.
114
 Second, the USPSTF recommended that women whose family history is 
associated with an increased risk for deleterious mutations in BRCA1/2 genes be referred for 
genetic counseling and evaluation for BRCA testing.
115
 In weighing the clinical utility of routine 
BRCA1/2 mutation testing for women without certain specific family history patterns, the 
USPSTF found that any benefit to routine screening or routine referral for genetic counseling 
would be small or zero.
116
 As mentioned above, the prevalence of BRCA1/2 mutations among 
average risk and moderate risk women is only .24% and .24% to 3.4%, respectively.
117
 These 
numbers are too low to warrant a recommendation for routine screening. Moreover, the USPSTF 
found substantial evidence regarding important adverse ethical, legal, and social consequences 
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that could result from routine referral and testing of these women.
118
 The USPSTF estimated that 
the magnitude of the potential harms associated with interventions such as prophylactic surgery, 
chemoprevention, or intensive screening is small or greater.
119
 Thus, the USPSTF concluded that 
the potential harms of routine referral for genetic counseling or BRCA testing in these women 
outweigh the benefits.
120
 As to the second recommendation, the USPSTF found that women with 
certain specific family history patterns would benefit from genetic counseling. The task force 
believes that counseling will give these women an opportunity to make informed decisions about 
testing and further prophylactic treatment.  
B. Recommendations of Other Professional Medical Groups 
 Four other organizations have made recommendations on genetic susceptibility testing. 
The American College of Medical Genetics (ACMG) recommends risk assessment and genetic 
counseling before testing for BRCA1/2 mutations in individuals at increased risk, based on a 
personal or family history of breast cancer, ovarian cancer, or both.
121
 The National 
Comprehensive Cancer Network recommends offering genetic susceptibility testing to individuals 
who meet the criteria for hereditary breast or ovarian cancer or both.
122
 The American Society of 
Clinical Oncology recommends that genetic testing be offered when: 1) an individual has a 
personal or family history that suggests a genetic cancer susceptibility; 2) the test can be 
adequately interpreted and its results will influence diagnosis or management of the patient or 
family members at risk for hereditary cancer.
123
 The American College of Obstetrician and 
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Gynecologists Committee Opinion (ACOG) on breast and ovarian cancer screening, written in 
2000, recommends offering BRCA mutation testing to families in which multiple family members 
have had breast or ovarian cancer or in which a BRCA mutation has been found.
124
 The 
recommendations of each of these groups are analogous to the USPSTF recommendations in that 
they only recommend BRCA testing when the patient falls into a high-risk category. 
 In sum, there are five different professional medical organizations that recommend BRCA 
testing only when a woman falls into a high-risk category. Despite this apparent plethora of 
information for doctors and patients, these groups seem disconnected from the overall message. 
The following section discusses issues related to doctor and patient use and understanding of 
clinical guidelines for genetic predisposition screening. 
IV. Problems Related to Physician and Patient Use and Understanding of Genetic 
Screening for Cancer Susceptibility 
A. Primary Care Physicians 
 The purpose of the USPSTF’s recommendations is to improve care by providing national 
guidelines for doctors. It is often difficult for doctors to keep up with the most recent literature, 
especially in areas beyond their specific area of concentration. Thus, the recommendations and 
guidelines released by the USPSTF are important to catch doctors up on the latest procedures 
and practices to promote more efficient and effective care. For example, when it comes to 
susceptibility testing for diseases such as breast and ovarian cancer, interpretations of genetic 
tests require sophisticated knowledge that many primary care providers may lack. In fact, 
physician knowledge of genetics has been low in self-reported surveys and in direct 
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assessment.
125
 Only 37% regularly read articles on genetic testing.
126
  Interestingly, despite the 
USPSTF recommendation discussed above, 89% of physicians have indicated needs for clinical 
guidelines for genetic testing for cancer susceptibility.
127
 Physicians also expressed concern for 
insurance discrimination, confidentiality.
128
 Finally, most physicians believe that their 
responsibilities include counseling patients about genetic testing, but only 51% have time to do 
so.
129
 These numbers show not only that doctors recognize the importance of genetics regardless 
of their field of medicine, but also that doctors feel they have inadequate resources to meet the 
demands of their practice. 
 Although doctors seem to have serious concerns with respect to genetic testing, doctors 
continue to order genetic tests and referrer patients for testing. One study has suggested that 60% 
of primary care physicians have ordered genetic test, and 74% have referred a patient for 
testing.
130
 There seems to be a serious disconnect between what doctors feel and do with respect 
to genetic testing. Many factors are involved in whether physicians order tests, including patient 
inquiry about testing, provider assessment of the probability of a patient’s carrying a mutation, 
and practice environment.
131
 Referral for cancer susceptibility tests has been associated with 
patient request and physicians receiving genetic test advertising.
132
  
 Understanding the issues related to physicians and their attitudes and practices concerning 
genetic testing is important in the discussion of the USPSTF recommendations. Klitzman says 
clinical guidelines for utilization of genetic testing are increasingly being developed, but it is 
unclear how many physicians are aware of these guidelines, or in what specific areas they see 
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themselves as needing training.
133
 The USPSTF, ACMG, and others cannot achieve their goal of 
educating doctors and promoting efficient and effective health care if doctors are not even aware of 
the guidelines or how to apply them. It is important that doctors are driven to ordering tests for the 
right clinical reasons, and not by other uninformed motivations. 
B. Patients 
Recent developments in science and technology have captured the public consciousness. 
With news coverage of advances in genetics, and direct-to-consumer (DTC) marketing of tests, 
patients’ interest in testing will no doubt continue to grow.134 Despite a growing interest in 
testing, patients still have serious misconceptions about testing and their risk for cancer 
susceptibility. Women often overestimate their risks for breast cancer or BRCA mutations and 
most women responding to surveys, including women at average and moderate risk, report a 
strong desire for genetic testing even though only those at high risk would potentially benefit.
135
 
Ultimately, the USPSTF hopes that its guidelines lead to better care for patients. But, as doctors, 
rather than patients, are the targeted audience for its recommendation, it is unclear if patients 
have any knowledge of the USPSTF guidelines. Perhaps the USPSTF needs to do more to 
promote its recommendations and expand its targeted audience. Whether patients would heed the 
advice of the USPSTF or even understand the guidelines and the technical reasoning behind the 
recommendation is unclear. 
V. Author’s Recommendation 
In order to meet the growing demand of information regarding genetic testing for cancer 
susceptibility, certain programs and initiatives need to be developed to educate doctors and 
patients. Within the medical profession, organizations, such as the USPSTF, American College 
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of Medical Genetics, and others, need to create educational programs for doctors, especially 
primary care physicians who are often on the frontline in assessing risk for cancer susceptibility 
among patients. For example, one recommendation is that practicing physicians should be 
required to attend continuing education seminars on advancements in genetics once every five 
years. Additionally, current medical students could be required to take multiple genetics classes 
so they are prepared to meet the demand for information regarding cancer susceptibility once 
they begin practicing medicine.  
On the other side of the issue, in order to better educate patients, the USPSTF could push 
for publication of its clinical guidelines for genetic predisposition testing in more widely 
circulated streams of media and social media. Furthermore, it can be expected that information 
passed on doctors will eventually trickle down to patients. 
Conclusion 
 Practice and procedural guidelines provide an invaluable resource to physicians. In the 
field of genetics, the recommendations of the USPSTF are especially important in guiding how 
physicians tackle the issue of genetic testing cancer susceptibility. Armed with these 
recommendations and the scientific data to support them, doctors can provide better care to their 
patients. Studies have shown that the clinical utility of BRCA1/2 mutation testing is greatly 
outweighed by the adverse effects of testing among women that do not belong to specific high-
risk groups. Nevertheless, there is a gap between the recommendations and the actions of 
physicians and patients. Hopefully, with the use of greater educational programs and resources 
for physicians and greater outreach by the medical community to the general public, practices 
can be improved to fall in line with the recommendations of the USPSTF. 
